Remote-controlled CAR-T cells use venetoclax to disengage from tumors

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their promise, CAR-T cells do have their limitations….

Continue Reading


News Source: medicalxpress.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *